Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C virus resistance to the new direct-acting antivirals

6 Jul 2016

Abstract excerpt

INTRODUCTION: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens. Despite the high sustained virological response (SVR) rates (over 90%) obtained with direct-acting antivirals (DAAs), drug resistance has emerged as a potential challenge. The high replication rate of HCV and the low fidelity of its RNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C virus research
Share to HIV/AIDS drug development and treatment
Share to Silymarin and Mushroom Poisoning

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27384079
DOI: 10.1080/17425255.2016.1209484

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C virus resistance to the new direct-acting antiviralsPMID 27384079Read ↗

Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.Semantic proximity Read ↗

Resistance to direct-acting antiviral agents: clinical utility and significance.Semantic proximity Read ↗

Update on hepatitis C virus resistance to direct-acting antiviral agents.Semantic proximity Read ↗

Resistance to direct antiviral agents in patients with hepatitis C virus infection.Semantic proximity Read ↗

[RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].Semantic proximity Read ↗

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.Semantic proximity Read ↗

Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.Semantic proximity Read ↗

[Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].Semantic proximity Read ↗

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Semantic proximity Read ↗

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.Semantic proximity Read ↗

Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals.Semantic proximity Read ↗

Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.